CHEMOMAB THERAPEUTICS LTD(NASDAQ:CMMB) stock News

CMMB Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Chemomab Therapeutics

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Benzinga - Mentions: ACET CLDX ALC BLRX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a month ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Chemomab Therapeutics

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

3 months ago - By: Chemomab Therapeutics

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

3 months ago - By: Chemomab Therapeutics

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

3 months ago - By: Chemomab Therapeutics

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

4 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN KURA

KURA Stock Rises More Than 15% This Past Week: Here's Why

4 months ago - By: Zacks Investment Research - Mentions: LXRX TPST

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

4 months ago - By: Chemomab Therapeutics

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

4 months ago - By: Zacks Investment Research - Mentions: MRK LXRX

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

4 months ago - By: Zacks Investment Research - Mentions: REGN LXRX NTLA

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

4 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN CADL

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

4 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN RCKT

RCKT Stock Tanks on Patient Death in Danon Disease Study

4 months ago - By: Zacks Investment Research - Mentions: TEVA LXRX AMRN

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

4 months ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Chemomab Therapeutics

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

5 months ago - By: Chemomab Therapeutics

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

5 months ago - By: Chemomab Therapeutics

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

5 months ago - By: Chemomab Therapeutics

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

5 months ago - By: Chemomab Therapeutics

Chemomab Announces New Medical and Clinical Appointments

6 months ago - By: Benzinga

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

6 months ago - By: Chemomab Therapeutics